Teriparatide Injection, Solution
Product Images NDC 0093-1106

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Teriparatide (NDC 0093-1106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Chemical structure diagram of Teriparatide showing the sequence of amino acids from the N-terminus (H-) to the C-terminus (-OH) arranged in a linear peptide chain and labeled with residue numbers 1, 5, 10, 15, 20, 25, and 30.*

FDA Label Image

1 (Image 10)

An instructional illustration showing a hand holding an injection pen with a focus on the red stripe indicator on the pen. The image highlights the position of the red stripe for correct use or identification of the injection pen device.*

FDA Label Image

1 (Image 11)

An instructional illustration showing a hand holding a syringe with a small needle protector being removed. The image highlights the small needle protector on the syringe, indicating a step likely related to preparing the injection for use.*

FDA Label Image

1 (Image 12)

An instructional illustration showing a person administering a subcutaneous injection using a pen device. The image depicts the hand holding the injection pen and positioning it at an angle to the skin surface, preparing to inject medication.*

FDA Label Image

1 (Image 13)

An instructional illustration showing a person holding a pen-like device for subcutaneous injection. The image features an arrow pointing to the device and a speech bubble with a counting sequence from 1 to 5, indicating a timed or stepwise action during use.*

FDA Label Image

1 (Image 14)

An instructional illustration showing a hand holding a pen-like injection device with the cap highlighted by a blue circle. This is likely related to preparing or using the Teriparatide injection solution pen for subcutaneous administration.*

FDA Label Image

1 (Image 15)

An instructional illustration showing a hand holding an injection pen with a red prohibition symbol over the top part of the pen, indicating an action not to be performed with the injection device.*

FDA Label Image

1 (Image 16)

An instructional illustration showing a hand holding a Teriparatide injection pen, with an arrow pointing to a detached large needle cover nearby, indicating its removal before use.*

FDA Label Image

1 (Image 17)

An instructional illustration showing hands preparing a Teriparatide injection pen. One hand holds the pen steady while the other hand rotates the dosing knob or cap, indicated by a red circular arrow, demonstrating the action to adjust or unlock the pen before use.*

FDA Label Image

1 (Image 18)

An instructional illustration showing a hand holding a Teriparatide injection pen, with the other hand removing the cap from the needle. The image visually guides how to prepare the injection device before administration.*

FDA Label Image

1 (Image 19)

An instructional illustration showing a hand holding a Teriparatide injection pen and another hand removing the protective cap by pulling it off. The image demonstrates the step to prepare the Teriparatide subcutaneous injection for use by removing its cap.*

FDA Label Image

1 (Image 2)

A line chart showing the percent of patients with nonvertebral osteoporotic fractures over 20 months since randomization. Two lines compare Teriparatide (dashed line) and Placebo (solid line). The y-axis indicates the percent of patients with fractures, and the x-axis shows months since randomization.*

FDA Label Image

1 (Image 20)

The image shows a teal and yellow injection pen for Teriparatide 250 mcg/mL by Teva Pharmaceuticals USA, Inc. It is a subcutaneous injection device with a protective cap on one end and a dose selector at the opposite end. The label area is blank in this image.*

FDA Label Image

1 (Image 21)

FDA Label Image

1 (Image 22)

An instructional illustration indicating not to cover or block the top of an injection device with a cap or barrier. The image features a hand holding an injectable pen and a red prohibition circle with a slash over the cap area, emphasizing proper handling precautions.*

FDA Label Image

1 (Image 23)

FDA Label Image

1 (Image 24)

FDA Label Image

1 (Image 25)

FDA Label Image

1 (Image 26)

FDA Label Image

1 (Image 27)

Teriparatide Injection carton label for 20 mcg per dose given once daily subcutaneously, containing 600 mcg/2.4 mL (250 mcg/mL) solution in a single-patient-use prefilled pen. Label indicates refrigeration and subcutaneous use only, manufactured for Teva Pharmaceuticals USA, Inc., with product NDC 0093-1106-16. The carton also includes a small illustration of the prefilled pen.*

FDA Label Image

1 (Image 3)

Illustration diagram of a pen injection device broken down into labeled parts including the black injection button, yellow shaft, red stripe, main body, medicine cartridge, and blue cap. Below, components associated with needles are shown: paper tab, needle, small needle protector, and large needle cover, with a note stating needles are not included and recommending specific pen needles for use with the device.*

FDA Label Image

1 (Image 4)

An instructional diagram illustrating the removal of a cap or cover from a pen-style injection device. Two hands are shown: one holding the pen while the other pulls off the cap, indicated by an arrow pointing away from the device.*

FDA Label Image

1 (Image 5)

An instructional line drawing showing two hands handling a vial and a syringe, likely demonstrating how to prepare an injection dose, associated with Teriparatide 250 mcg/mL injection solution for subcutaneous use by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

1 (Image 6)

An instructional illustration showing the preparation step for a Teriparatide injection. It depicts a hand holding an injection pen and another hand pulling off a protective cap from the device, indicated by an arrow pointing away from the pen.*

FDA Label Image

1 (Image 7)

An instructional illustration showing a hand holding and twisting the cap of an injection pen, depicting the action of removing or securing the pen cap with a curved red arrow indicating the twisting motion. The image relates to the use of a subcutaneous injection device, consistent with Teriparatide injection.*

FDA Label Image

1 (Image 8)

An instructional illustration showing a hand removing the large needle cover from a Teriparatide injection pen, highlighting the needle cover and its position relative to the pen.*

FDA Label Image

1 (Image 9)

An instructional illustration showing two hands holding a small injection vial or cartridge. One hand is gripping the vial at the top, while the other hand is positioned at the bottom, pressing downwards, indicated by a downward arrow below the vial. The image likely depicts part of the preparation or administration process of a subcutaneous injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.